c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

Di, Bacco A. ✉; Bahlis, N.J.; Munshi, N.C.; Avet-Loiseau, H.; Masszi, T. [Masszi, Tamás (Belgyógyászat, ha...), author] III. Department of Internal Medicine (SU / FM / C); Viterbo, L.; Pour, L.; Ganly, P.; Cavo, M.; Langer, C.; Kumar, S.K.; Rajkumar, S.V.; Keats, J.J.; Berg, D.; Lin, J.; Li, B.; Badola, S.; Shen, L.; Zhang, J.; Esseltine, D.-L.; Luptakova, K.; van, de Velde H.; Richardson, P.G.; Moreau, P.